MIDDLE EAST & NORTH AFRICA
We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2019 financial year.
United Arab Emirates
Contribution to Group revenue (%)
Revenue by segment (%)
- MENA growth will be mainly driven by Eqypt, UAE and Algeria over the next 3 years. Saudi Arabia is expected to be the largest market but the slowest growing
- The MENA reqion is expected to grow in USD by value at 5.4% p.a. 4 year CAGR between 2018 and 2022
Source: IQVIA Market Prognosis
Number of products launched:
In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
# The number of product launches has been restated to take into account discontinued operations.
|Total||1 056||1 032||2|
|Sterile Focus Brands||355||381||(7)|
Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.